Related Experiment Video
Updated: Jun 5, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
Does left ventricular diastolic function deteriorate earlier than left ventricular systolic function in anthracycline
Chetan D Patel1, Vijay Babu Balakrishnan, Lalit Kumar
1Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi-110029, India. chetantruptipatel@hotmail.com
Insights
Anthracycline chemotherapy can cause cardiotoxicity. This study found that left ventricular diastolic function (LVDF) declines before left ventricular systolic function (LVSF) in patients undergoing this treatment.
Area of Science:
- Cardiology
- Oncology
- Pharmacology
Background:
- Cardiotoxicity is a significant complication of anthracycline chemotherapy.
- Early detection of cardiac dysfunction is crucial for patient management.
Purpose of the Study:
- To investigate whether left ventricular diastolic function (LVDF) deteriorates earlier than left ventricular systolic function (LVSF) in patients receiving anthracyclines.
- To assess changes in cardiac function during anthracycline treatment.
Main Methods:
- Prospective study of 58 patients undergoing anthracycline chemotherapy.
- Evaluation of left ventricular systolic function (LVSF) using left ventricular ejection fraction (LVEF) and peak ejection rate (PER) via equilibrium radionuclide angiography (ERNA).
- Assessment of left ventricular diastolic function (LVDF) using peak filling rate (PFR) and other diastolic parameters from ERNA.
Main Results:
- A significant decrease in LVEF and PER was observed between cumulative doses of 139 mg/m² (S1) and 308 mg/m² (S2).
- A significant decrease in PFR was noted between baseline (S0) and 139 mg/m² (S1).
- These findings indicate an earlier decline in diastolic function compared to systolic function.
Conclusions:
- Left ventricular diastolic function (LVDF) deteriorates earlier than left ventricular systolic function (LVSF) in patients treated with anthracyclines.
- Monitoring LVDF may allow for earlier detection of cardiotoxicity during anthracycline chemotherapy.
Abstract:
Cardiotoxicity is the most important complication in patients receiving anthracycline chemotherapy. We studied the left ventricular diastolic function (LVDF) and systolic function (LVSF) in these patients and assessed whether LVDF deteriorates earlier than LVSF. We prospectively studied 58 patients (mean age 48.02 ± 13.87; 32 female, 26 male) on anthracycline treatment, before chemotherapy (S0) and after cumulative doses of 139 ± 12 mg/m(2) (S1) and 308 ± 14 mg/m(2) (S2). The LVSF was computed in terms of left ventricular ejection fraction (LVEF) from equilibrium radionuclide angiography (ERNA). The peak ejection rate (PER), peak filling rate (PFR), time to peak ejection rate (TPER), time to peak filling rate (TPFR), 1/3rd filling fraction and ratio of PFR and PER were calculated from ERNA and were also standardized using 150 baseline ERNA studies. Statistical analysis was done by repeated measures analysis of variance (ANOVA). We found significant decrease in LVEF (P<0.001) and PER (P<0.001) between the S1 and S2 studies and PFR (P<0.007) between the S0 and S1 studies. In conclusion in patients receiving anthracycline treatment, LVDF deteriorates earlier than left ventricular systolic function (LVSF).
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Heart Failure II: Pathophysiology
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Myocarditis I: Introduction
Mitral Regurgitation I: Introduction
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...

